Carminia Maria Della Corte Selected Research

Erlotinib Hydrochloride (CP 358,774)

4/2017	Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
1/2017	Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer.
1/2015	A multicenter, open-label phase II study of metformin with erlotinib in second-line therapy of stage IV non-small-cell lung cancer patients: treatment rationale and protocol dynamics of the METAL trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Carminia Maria Della Corte Research Topics

Disease

29	Neoplasms (Cancer) 11/2023 - 07/2013
23	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2024 - 07/2013
15	Lung Neoplasms (Lung Cancer) 04/2024 - 07/2013
8	Colorectal Neoplasms (Colorectal Cancer) 10/2023 - 11/2014
4	Bites and Stings (Sting) 04/2024 - 01/2019
4	Carcinogenesis 12/2022 - 11/2014
4	COVID-19 01/2022 - 10/2020
3	Malignant Mesothelioma 12/2022 - 04/2018
3	Neoplasm Metastasis (Metastasis) 04/2018 - 01/2018
2	Disease Progression 10/2023 - 01/2023
2	Cardiotoxicity 01/2023 - 06/2021
2	Squamous Cell Carcinoma of Head and Neck 01/2022 - 08/2021
2	Communicable Diseases (Infectious Diseases) 11/2021 - 01/2021
1	Hemangiosarcoma (Angiosarcoma) 01/2024
1	Airway Obstruction (Choking) 01/2023
1	Hypoxia (Hypoxemia) 01/2023
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2023
1	Pathologic Constriction (Stenosis) 01/2023
1	Hemorrhage 01/2023
1	Hypercapnia 01/2023
1	Adenocarcinoma of Lung 11/2022
1	Pneumothorax 01/2022
1	Heart Arrest (Cardiac Arrest) 12/2021
1	Anemia 12/2021
1	Intraoperative Complications 12/2021
1	Wound Infection (Wound Infections) 12/2021
1	Hepatocellular Carcinoma (Hepatoma) 09/2021
1	Neutropenia 05/2021
1	Craniopharyngioma (Craniopharyngiomas) 01/2021
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2021
1	Mesothelioma 04/2018
1	Neuroblastoma 01/2018
1	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2018

Drug/Important Bio-Agent (IBA)

10	ErbB Receptors (EGF Receptor)IBA 01/2023 - 07/2013
7	Biomarkers (Surrogate Marker)IBA 04/2024 - 01/2019
7	Cetuximab (Erbitux)FDA Link 01/2023 - 04/2017
6	Tyrosine Kinase InhibitorsIBA 01/2024 - 07/2013
6	Monoclonal AntibodiesIBA 11/2022 - 04/2017
5	Immune Checkpoint InhibitorsIBA 03/2022 - 01/2019
5	Metformin (Glucophage)FDA LinkGeneric 01/2017 - 07/2013
4	DNA (Deoxyribonucleic Acid)IBA 04/2024 - 01/2019
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 11/2022 - 01/2016
3	osimertinibIBA 01/2024 - 04/2017
3	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2018
3	InterferonsIBA 01/2023 - 01/2019
3	CytokinesIBA 11/2022 - 06/2019
3	avelumabIBA 03/2022 - 01/2020
3	Gefitinib (Iressa)FDA Link 04/2017 - 07/2013
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 04/2017 - 01/2015
2	trifluridine tipiracil drug combinationIBA 10/2023 - 01/2023
2	Panitumumab (Vectibix)FDA Link 10/2023 - 01/2023
2	RNA (Ribonucleic Acid)IBA 05/2023 - 01/2023
2	pembrolizumabIBA 01/2023 - 06/2021
2	NivolumabIBA 01/2023 - 06/2021
2	Phosphotransferases (Kinase)IBA 12/2022 - 06/2014
2	Membrane Proteins (Integral Membrane Proteins)IBA 11/2021 - 01/2021
2	Growth Factor ReceptorsIBA 01/2019 - 11/2014
2	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 11/2018 - 11/2014
2	KisspeptinsIBA 04/2018 - 01/2018
2	MetalsIBA 01/2017 - 01/2015
2	Hypoglycemic Agents (Hypoglycemics)IBA 11/2013 - 07/2013
1	Glucose (Dextrose)FDA LinkGeneric 11/2023
1	EnzymesIBA 11/2023
1	Biocompatible Materials (Biomaterials)IBA 05/2023
1	Interferon-gamma (Interferon, gamma)IBA 01/2023
1	Antiviral Agents (Antivirals)IBA 01/2023
1	encorafenibIBA 01/2023
1	tyrosine receptor (receptor, tyrosine)IBA 12/2022
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 12/2022
1	Immunoglobulin G (IgG)IBA 03/2022
1	tyramine-deoxysorbitolIBA 01/2022
1	cupric sulfide (CuS)IBA 01/2022
1	Angiogenesis InhibitorsIBA 01/2022
1	IpilimumabIBA 06/2021
1	atezolizumabIBA 06/2021
1	durvalumabIBA 06/2021
1	cemiplimabIBA 06/2021
1	dabrafenibIBA 01/2021
1	trametinibIBA 01/2021
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2020
1	Interleukin-6 (Interleukin 6)IBA 06/2019
1	EphA2 ReceptorIBA 01/2019
1	ALW-II-41-27IBA 01/2019
1	ParaffinIBA 01/2019
1	Formaldehyde (Formol)FDA Link 01/2019
1	Peptides (Polypeptides)IBA 04/2018
1	ceritinibIBA 01/2018
1	Anaplastic Lymphoma KinaseIBA 01/2018
1	CrizotinibIBA 01/2018

Therapy/Procedure

20	Therapeutics 11/2023 - 11/2013
13	Immunotherapy 04/2024 - 11/2018
9	Drug Therapy (Chemotherapy) 04/2024 - 11/2013
6	Radiotherapy 05/2023 - 03/2015
1	Combined Modality Therapy 01/2024
1	Airway Management 01/2023
1	Lasers (Laser) 01/2023
1	Precision Medicine 01/2022
1	Heart Massage 12/2021
1	Blood Transfusion (Blood Transfusions) 12/2021
1	Continuity of Patient Care 09/2021